Why Alzheimer’s Was Traditionally Considered Irreversible

Alzheimer’s disease was traditionally viewed as a neurodegenerative disorder that could only move in one direction. Once memory declined, the goal was usually to slow the process rather than improve function.

This belief became stronger because many drug trials failed to restore memory. Even newer monoclonal antibody drugs, which remove amyloid plaque, have not restored lost cognitive function. They may slow decline in selected patients, but slowing decline is not the same as improving function.

That difference is critical. A treatment that delays decline by several months is not the same as a treatment strategy that helps the brain perform better.

The Problem With Focusing Only on Slowing Decline

One of the most important developments in Alzheimer's disease over the last several years has been the introduction of monoclonal antibody drugs such as lecanemab (Leqembi®) and donanemab (Kisunla®).

These medications represent a remarkable scientific achievement because they clearly demonstrate that amyloid plaque can be removed from the brain.

However, removing amyloid plaque and restoring cognitive function are not the same thing.

Although Leqembi® and Kisunla® have demonstrated statistically measurable slowing of decline, the real-world effect for many families is surprisingly modest. Over approximately 18 months, the average benefit may translate into a delay of symptoms measured in months rather than years. Importantly, the disease itself continues to progress.

For many patients and families, that difference may be difficult to recognize in everyday life.

Consequently, patients should understand that there is a fundamental distinction between slowing decline and improving function.

Those are not the same goal.

What the EVANTHEA Precision Medicine Trial Changed

The EVANTHEA Precision Medicine Trial changed the conversation because it demonstrated something fundamentally different from the newest infusion therapies.

Leqembi® and Kisunla® primarily aim to slow decline.

By contrast, the EVANTHEA approach demonstrated improvement.

That distinction is profound.

Improvement is not simply slower deterioration.

It means better cognitive performance, better testing scores.

Improvement means better function.

When viewed side by side, the results reported with Precision Medicine compare favorably to the outcomes reported with monoclonal antibody therapies. In fact, the strongest results reported with Kisunla® are similar to the weakest improvements observed in the EVANTHEA study.

This comparison is important because it highlights the difference between delaying decline and creating the possibility of meaningful improvement.

That does not mean infusion therapies have no role. However, it does suggest that patients and families should ask an important question:

If meaningful improvement is possible, why settle for merely slowing decline?

Why Time Matters

Time is one resource that patients can never recover.

Neurodegeneration does not pause while treatment decisions are being made.

Therefore, every month spent pursuing approaches whose primary objective is merely slower decline may represent lost time that could have been devoted to identifying and addressing the factors affecting brain health.

Earlier intervention generally creates more opportunities.

Waiting rarely creates additional opportunities.

Acting early often does.

The Carroll Institute Perspective

At the Carroll Institute, we believe the goal should not simply be to decline more slowly.

The goal should be to improve whenever improvement is possible.

That philosophy is one of the central principles of the Carroll Cognitive Method™.

Instead of asking:

"How much can we slow this disease?"

we ask:

"How much function can we restore?"

Those are very different questions.

And they lead to very different treatment philosophies.

At the Carroll Institute, we believe patients deserve to pursue improvement whenever meaningful improvement is possible. Time spent pursuing a strategy that only slows decline may be time lost from implementing a more comprehensive Precision Medicine approach.

Alzheimer’s Disease Is Not One Simple Disease

One reason a single drug is unlikely to solve Alzheimer’s disease is that cognitive decline usually involves many variables. Dr. Dale Bredesen and others have described dozens of contributors that may drive cognitive decline in different patients.

One person may have insulin resistance. Another may have chronic inflammation. A third may have sleep apnea, vascular disease, mold exposure, hormonal imbalance, or heavy metal toxicity. Many patients have several contributors at the same time.

Consequently, expecting one drug to address every unique combination of these variables is not realistic for most patients. Alzheimer’s disease behaves more like a systems breakdown than a single drug deficiency.

Amyloid May Matter, But It Is Not the Whole Story

Amyloid plaque may be an important biomarker, contributor, or response mechanism. However, the clinical results of amyloid-removing therapies suggest that amyloid alone is unlikely to explain the full disease process.

The bigger question is not simply, “How do we remove amyloid?” The better question is: why is the brain producing amyloid in the first place?

If inflammation, infection, metabolic dysfunction, vascular problems, toxins, sleep disorders, or immune activation are driving the process, then removing amyloid alone may be like reducing swelling after an ankle injury without repairing the damaged tissue.

Neuroplasticity Makes Improvement Possible

Another reason improvement may be possible is neuroplasticity. Neuroplasticity is the brain’s ability to adapt, reorganize, strengthen existing pathways, and build new connections.

For many years, people believed the adult brain was fixed. We now know that the brain can change throughout life. It can learn, adapt, and respond to targeted stimulation.

At the Carroll Institute, we often describe neuroplasticity as a turbocharger for Precision Medicine. Precision Medicine identifies what is interfering with brain health. Functional Neurology helps stimulate and rehabilitate the brain networks that need support.

Root Causes Matter

Alzheimer’s disease and MCI often share many of the same underlying contributors. The label may change, yet the root-cause investigation remains essential.

Common contributors may include:

• Chronic inflammation
• Insulin resistance
• Sleep apnea or poor sleep quality
• Vascular dysfunction
• Hormonal imbalances
• Nutritional deficiencies
• Mold exposure
• Heavy metals and environmental toxins
• Chronic stress
• Brain network dysfunction

Because each patient has a different combination of contributors, each patient needs an individualized plan. This is the foundation of Precision Medicine.

Why Timing Matters

Time matters in cognitive decline. Neurodegeneration does not pause while families decide what to do.

Earlier intervention usually creates more opportunities. More neuroplasticity may remain available. More brain reserve may still exist. In addition, root causes may be easier to address before decline becomes advanced.

That does not mean people with Alzheimer’s disease cannot improve. Many can. However, waiting rarely creates additional options. Acting early often does.

The Carroll Cognitive Method™ Perspective

The Carroll Cognitive Method™ was developed around a different way of thinking about cognitive decline. Instead of viewing Alzheimer’s disease as a single-target disease, we view it as a systems problem affecting the brain.

The method combines three disciplines:

Precision Medicine

Precision Medicine identifies the specific biological contributors affecting each patient’s brain health.

Functional Medicine

Functional Medicine addresses root causes such as inflammation, metabolic dysfunction, sleep problems, hormonal imbalance, nutritional deficiencies, and environmental exposures.

Functional Neurology

Functional Neurology evaluates how the brain is functioning and uses targeted rehabilitation strategies to support neuroplasticity and brain network performance.

Together, these disciplines allow us to ask a better question: what is preventing this brain from improving?

Hope Without False Promises

Is Alzheimer’s disease reversible?

In some patients, meaningful improvement is possible.

Still, every patient is different. Advanced neurodegeneration, trauma, severe vascular insufficiency, poor compliance, genetics, and other medical factors may affect outcomes. Therefore, no responsible clinician should promise that every person will improve in the same way.

Even so, the old message of hopeless decline is no longer acceptable. Patients deserve a deeper investigation. They deserve a more complete explanation. Most importantly, they deserve a plan that looks for the reasons their brain is struggling.

Next Steps

If you or someone you love has been diagnosed with Alzheimer’s disease, Mild Cognitive Impairment, or progressive memory loss, the Carroll Institute can help you explore whether the Carroll Cognitive Method™ may be appropriate.

The question is not simply whether Alzheimer’s disease can improve. Increasing evidence suggests that it can for many patients.

The better question is: what factors are preventing this particular brain from improving?

Sources

• EVANTHEA Precision Medicine Trial — ClinicalTrials.gov
  https://clinicaltrials.gov/study/NCT05894954
• Precision Medicine Approach to Alzheimer's Disease: Rationale and Implications — Journal of Alzheimer's Disease
  https://pubmed.ncbi.nlm.nih.gov/37807782/
• Neuroplasticity and the Brain — NCBI Bookshelf
  https://www.ncbi.nlm.nih.gov/books/NBK20367/
• Mild Cognitive Impairment Diagnosis and Treatment — Mayo Clinic
  https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/diagnosis-treatment/drc-20354583
• Carroll Cognitive Method™
  https://thecarrollinstitute.com/tci-recode-program
• Dr. Garland Glenn
  https://thecarrollinstitute.com/about-dr-garland-glenn
• What Happens to the Brain in Alzheimer's Disease?
  https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
• Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development
  https://pubmed.ncbi.nlm.nih.gov/36442193/
• Alzheimer's Disease and the Immune System
  https://pmc.ncbi.nlm.nih.gov/articles/PMC12035277/

Medical Disclaimer

This information is provided for educational purposes only and is not intended as medical advice. Individual outcomes vary. No specific result can be guaranteed. Patients should consult a qualified healthcare professional regarding their individual medical situation.

Reviewed by: Dr. Garland Glenn, DC, PhD, IFM, AFMC

Location: Sarasota, Florida

Last Updated: June 19, 2026